A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple negative breast cancer

被引：1
|
作者：
Telli, M. L.
Wapnir, I.
Vinayak, S.
Chang, J.
Alemany, C.
Twitty, C.
Gargosky, S.
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Houston Methodist Canc Ctr, Houston, TX USA
[4] Florida Hosp Canc Inst, Orlando, FL USA
[5] OncoSec Med, San Diego, CA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-OT2-06-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-06-03
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Intratumoral tavokinogene telseplasmid and electroporation in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer
    Telli, M. L.
    Zablotsky, K.
    Le, M. H.
    Canton, D.
    Browning, E.
    Bannavong, D.
    Gargosky, S.
    Wapnir, I.
    CANCER RESEARCH, 2019, 79 (04)
  • [2] Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE-890/OMS-I141)
    Telli, Melinda L.
    Wapnir, Irene
    Devitt, Bianca
    Cuff, Katharine
    Soliman, Hatem
    Vinayak, Shaveta
    Canton, David A.
    Twitty, Christopher
    Foerter, Kellie Malloy
    Joshi, Rohit
    CANCER RESEARCH, 2020, 80 (04)
  • [3] Trial in progress: Phase 2 study of intratumoral plasmid interleukin-12 (tavokinogene telseplasmid; TAVO™) plus electroporation in combination with pembrolizumab with or without chemotherapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (KEYNOTE-890/OMS-I141)
    Telli, Melinda
    Devitt, Bianca
    Cuff, Katharine
    Vinayak, Shaveta
    Nanda, Rita
    Montero, Alberto J.
    Hui, Rina
    Canton, David A.
    Twitty, Christopher
    Xie, Sunny
    Bannavong, Donna
    O'Keeffe, Bridget
    Aung, Sandra
    Joshi, Rohit
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Results of phase I study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple negative breast cancer.
    Chumsri, Saranya
    He, Jun
    Hillman, David
    Weidner, Morgan
    Weidner, Morgan
    Haley, Dana
    Reis, Aline
    Tenner, Kathleen
    Advani, Pooja
    Sideras, Kostandinos
    Moreno-Aspitia, Alvaro
    Perez, Edith
    Knutson, Keith
    CANCER RESEARCH, 2021, 81 (13)
  • [5] Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer
    Chumsri, Saranya
    Larson, Joseph J.
    Tenner, Kathleen S.
    He, Jun
    Polley, Mei-Yin
    Weidner, Morgan T.
    Arnold, Amanda N.
    Haley, Dana
    Advani, Pooja
    Sideras, Kostandinos
    Moreno-Aspitia, Alvaro
    Perez, Edith A.
    Knutson, Keith L.
    CANCER RESEARCH, 2023, 83 (05)
  • [6] Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer
    Chumsri, Saranya
    Larson, Joseph
    Adams, Daniel
    Tenner, Kathleen
    Tang, Cha-Mei
    Weidner, Morgan
    Arnold, Amanda
    Haley, Dana
    Advani, Pooja
    Sideras, Kostandinos
    Moreno-Aspitia, Alvaro
    Perez, Edith
    Knutson, Keith
    CANCER RESEARCH, 2024, 84 (09)
  • [7] Intratumoral plasmid IL-12 and electroporation in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer (TNBC)
    Telli, Melinda L.
    Zablotsky, Kaitlin
    Gargosky, Sharron E.
    Twitty, Christopher G.
    Wapnir, Irene L.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer
    Chumsri, Saranya
    Polley, Mei-Yin
    Mathur, Pulkit
    Reis, Aline
    Tenner, Kathleen S.
    Weidner, Morgan
    Advani, Pooja
    Moreno-Aspitia, Alvaro
    Perez, Edith A.
    Knutson, Keith L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [9] Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia G.
    D'Adamo, David R.
    Aktan, Gursel
    Tsai, Michaela L.
    O'Regan, Ruth M.
    Kaufman, Peter A.
    Wilks, Sharon T.
    Andreopoulou, Eleni
    Patt, Debra A.
    Yuan, Yuan
    Wang, Grace
    Savulsky, Claudio
    Xing, Dongyuan
    Kleynerman, Ella
    Karantza, Vassiliki
    Diab, Sami
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3061 - 3068
  • [10] Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
    Cortes, J.
    Rugo, H. S.
    Cescon, D. W.
    Im, S-A
    Yusof, M. M.
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Perez-Garcia, J.
    Iwata, H.
    Masuda, N.
    Otero, M. Torregroza
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Zhou, X.
    Karantza, V
    Pan, W.
    Schmid, P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03): : 217 - 226
12345